Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CAO Kelly Macdonald sold 987 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $11.00, for a total transaction of $10,857.00. Following the sale, the chief accounting officer now owns 78,444 shares in the company, valued at $862,884. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ:IRWD traded up $0.02 during trading on Wednesday, reaching $11.37. 23,429 shares of the company were exchanged, compared to its average volume of 1,583,573. The firm has a market capitalization of $1.73 billion, a PE ratio of -12.02 and a beta of 1.80. The business’s fifty day simple moving average is $9.31 and its 200-day simple moving average is $10.08. Ironwood Pharmaceuticals, Inc. has a 12-month low of $7.91 and a 12-month high of $15.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, October 31st. The biotechnology company reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.30. The business had revenue of $131.17 million for the quarter, compared to analyst estimates of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. The company’s quarterly revenue was up 99.7% compared to the same quarter last year. During the same period last year, the company posted ($0.27) earnings per share. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.49 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. First Trust Advisors LP bought a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $756,000. AQR Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 181.9% during the second quarter. AQR Capital Management LLC now owns 149,888 shares of the biotechnology company’s stock valued at $1,640,000 after purchasing an additional 96,719 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 3.4% during the third quarter. Peregrine Capital Management LLC now owns 1,274,690 shares of the biotechnology company’s stock valued at $10,943,000 after purchasing an additional 41,908 shares in the last quarter. Signition LP bought a new position in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $100,000. Finally, EcoR1 Capital LLC boosted its stake in shares of Ironwood Pharmaceuticals by 6.2% during the second quarter. EcoR1 Capital LLC now owns 4,671,408 shares of the biotechnology company’s stock valued at $51,105,000 after purchasing an additional 274,240 shares in the last quarter.

A number of analysts recently weighed in on the stock. BidaskClub raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Wedbush increased their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. ValuEngine lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Cowen set a $12.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, September 13th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.50.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Further Reading: How is a Moving Average Calculated?

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.